Your browser doesn't support javascript.
Development and deployment of COVID-19 vaccines for those most vulnerable.
Koff, Wayne C; Schenkelberg, Theodore; Williams, Tere; Baric, Ralph S; McDermott, Adrian; Cameron, Cheryl M; Cameron, Mark J; Friemann, Matthew B; Neumann, Gabriele; Kawaoka, Yoshihiro; Kelvin, Alyson A; Ross, Ted M; Schultz-Cherry, Stacey; Mastro, Timothy D; Priddy, Frances H; Moore, Kristine A; Ostrowsky, Julia T; Osterholm, Michael T; Goudsmit, Jaap.
  • Koff WC; Human Vaccines Project, New York, NY 10119, USA. wkoff@humanvaccinesproject.org.
  • Schenkelberg T; Human Immunomics Initiative, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.
  • Williams T; Human Vaccines Project, New York, NY 10119, USA.
  • Baric RS; Human Immunomics Initiative, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.
  • McDermott A; Department of Pathology, Albert Einstein College of Medicine Bronx, NY 10461, USA.
  • Cameron CM; Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA.
  • Cameron MJ; Vaccine Immunology Program, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20814, USA.
  • Friemann MB; School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Neumann G; School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Kawaoka Y; Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD School of Medicine, Baltimore, MD 21201, USA.
  • Kelvin AA; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.
  • Ross TM; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.
  • Schultz-Cherry S; Institute of Medical Science, University of Tokyo, Bunkyo City, Tokyo 113-8654, Japan.
  • Mastro TD; Departments of Pediatrics, Microbiology and Immunology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
  • Priddy FH; Animal Health Research Center, Center for Vaccines, Immunology and Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
  • Moore KA; Infectious Diseases Research, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Ostrowsky JT; FHI 360, Durham, NC 27701, USA.
  • Osterholm MT; Vaccine Alliance Aotearoa New Zealand, Malaghan Institute of Medical Research, Wellington 6242, New Zealand.
  • Goudsmit J; Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis MN 55455, USA.
Sci Transl Med ; 13(579)2021 02 03.
Article in English | MEDLINE | ID: covidwho-1112312
ABSTRACT
Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Disease Susceptibility / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Scitranslmed.abd1525

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Disease Susceptibility / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Scitranslmed.abd1525